背景:胃癌的死亡率居恶性肿瘤第二位,寻求新的胃癌标记物和潜在的生物治疗靶点是目前胃癌的研究热点.目的:探讨miR-145在胃癌形成不同阶段中的表达及其临床意义.方法:选取2011年9月～2012年3月长宁区中心医院37例胃癌及其相应癌旁组织、8例慢性非萎缩性胃炎组织和7例异型增生组织,以RT-PCR法检测miR-145表达,并分析其与胃癌临床病理特征的关系.结果:与癌旁组织相比,胃癌组织中miR-145表达明显下调(P＜0.05)；与慢性非萎缩性胃炎组织相比,异型增生组织中miR-145表达明显下调(P＜0.05).胃癌组织miR-145表达与患者的性别、年龄、肿瘤浸润深度和淋巴结转移均无关(P＞0.05).结论:miR-145表达下调可能与胃癌的发生、发展相关.%Background: Gastric cancer is the second leading cause of cancer death. Seeking the new biomarkers and potential therapeutic targets has been the hot spot of gastric cancer research. Aims: To investigate the expression of miR-145 and clinical significance in the development of human gastric cancer. Methods: Thirty-seven cases of gastric cancer and corresponding para-cancerous tissue, 8 cases of chronic non-atrophic gastritis and 7 cases of dysplasia from September 2011 to March 2012 at Changning Center Hospital were enrolled. The expression of miR-145 was examined by RT-PCR, and its relationship with clinicopathologic features of gastric cancer was analyzed. Results: The expression of miR-145 was significantly decreased in gastric cancer tissue than that in para-cancerous tissue ( P < 0. 05 ) , and was significantly decreased in dysplasia tissue than that in chronic non-atrophic gastritis tissue (P < 0. 05). No significant correlation was found between the expression of miR-145 in gastric cancer and gender, age, depth of tumor invasion and lymph node metastasis (P>0.05). Conclusions: It is possible that down-regulation of miR-145 expression plays an important role in the development and progression of gastric cancer.
展开▼
